Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin ...

CRISPR Therapeutics has developed SyNTase editing, a proprietary, next-generation, site-specific gene correction platform.

The report provides a comprehensive analysis of the genome editing market, focusing on technologies like CRISPR-Cas, TALEN, ...

MB-111 is a potential first-in-class, single-dose in vivo CRISPR gene editing therapy for persistent chylomicronemiaOral presentation highlights safe, robust, and durable reduction of apoC-III and ...

Researchers engineered a CRISPR base editor to correct the ACTA2 mutation causing multisystemic smooth muscle dysfunction syndrome (MSMDS). In mouse models, a single dose of the therapy quadrupled ...

A team led by scientists at Harvard Medical School, Massachusetts General Hospital, and the Broad Institute of MIT and ...

The entire rationale behind this multi-pronged screening was the discovery of checkpoints or regulators that are critically involved in inducing suppression in NK cells under these diverse negative ...

One key finding is that deleting CDKN1B, a cell cycle regulator, increased CAR T cell proliferation and improved therapy persistence.

MB-111 is a potential first-in-class, single-dose in vivo CRISPR gene editing therapy for persistent chylomicronemia Oral presentation highlights safe, robust, and durable reduction of apoC-III ...

A single one-time gene therapy could free patients with α-thalassemia, a rare and debilitating blood disorder, from the ...